NASDAQ:ABVX Abivax (ABVX) Stock Price, News & Analysis $73.52 -7.13 (-8.84%) Closing price 03:58 PM EasternExtended Trading$74.15 +0.63 (+0.85%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Abivax Stock (NASDAQ:ABVX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abivax alerts:Sign Up Key Stats Today's Range$62.70▼$79.7450-Day Range$80.68▼$118.6452-Week Range$62.70▼$148.83Volume14.85 million shsAverage Volume1.43 million shsMarket Capitalization$6.44 billionP/E RatioN/ADividend YieldN/APrice Target$155.00Consensus RatingModerate Buy Company Overview Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally. Marc de Garidel has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Abivax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreABVX MarketRank™: 3.54549191559 of 5 starsAbivax scored higher than 71% of companies evaluated by MarketBeat, and ranked 225th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAbivax has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAbivax has a consensus price target of $155.00, representing about 115.2% upside from its current price of $72.04.Amount of Analyst CoverageAbivax has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Abivax's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Abivax are expected to decrease in the coming year, from ($4.14) to ($4.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abivax is -11.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abivax is -11.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbivax has a P/B Ratio of 10.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abivax's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.70% of the float of Abivax has been sold short.Short Interest Ratio / Days to CoverAbivax has a short interest ratio ("days to cover") of 4.63.Change versus previous monthShort interest in Abivax has recently decreased by 43.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbivax does not currently pay a dividend.Dividend GrowthAbivax does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.08 News SentimentAbivax has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Abivax this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for ABVX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows3 people have added Abivax to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Abivax insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of Abivax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abivax's insider trading history. Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abivax and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABVX Stock News HeadlinesAbivax Statement on Short Seller Report1 hour ago | globenewswire.comABVX INVESTOR ALERT: Investigation of Abivax S.A. Announced by Holzer & Holzer, LLC4 hours ago | globenewswire.comThis is likely to EXPLODEDr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.November 20 at 1:00 AM | Weiss Ratings (Ad)Abivax stock tumbles after Scorpion Capital report questions obefazimod safety4 hours ago | uk.finance.yahoo.comAbivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Drop in Short InterestNovember 19 at 4:20 AM | americanbankingnews.comAbivax SA Sponsored ADR (ABVX) - What Are Investment Firms Thinking About This Stock?November 10, 2026 | americanbankingnews.comAbivax to Participate in Upcoming Fall Investor ConferencesNovember 2, 2026 | globenewswire.comAbivax SA ADR ABVXOctober 23, 2026 | morningstar.comMSee More Headlines ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? Abivax's stock was trading at $134.85 at the beginning of 2026. Since then, ABVX stock has decreased by 46.6% and is now trading at $72.04. How were Abivax's earnings last quarter? Abivax SA Sponsored ADR (NASDAQ:ABVX) posted its quarterly earnings data on Monday, September, 21st. The company reported ($1.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by $0.79. The company earned $1.37 million during the quarter, compared to analysts' expectations of $799 thousand. When did Abivax IPO? Abivax (ABVX) raised $230 million in an IPO on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60-$13.00 per share. Who are Abivax's major shareholders? Top institutional shareholders of Abivax include RA Capital Management L.P. (1.18%), Logos Global Management LP (0.99%), Aberdeen Group plc (0.87%) and Two Seas Capital LP (0.77%). How do I buy shares of Abivax? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abivax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abivax investors own include Broadcom (AVGO), Marvell Technology (MRVL), Micron Technology (MU), Nebius Group (NBIS), NVIDIA (NVDA), Bloom Energy (BE) and MP Materials (MP). Company Calendar Last Earnings9/21/2026Today11/20/20269th Annual Evercore ISI HealthCONx Conference12/02/202638th Annual Healthcare Conference12/03/2026Next Earnings (Estimated)12/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ABVX's financial health is in the Yellow zone, according to TradeSmith. ABVX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees98Year Founded2013Price Target and Rating Average Price Target for Abivax$155.00 High Price Target$187.00 Low Price Target$96.00 Potential Upside/Downside+110.8%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($6.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$380.27 million Net MarginsN/A Pretax Margin-33,207.73% Return on Equity-91.69% Return on Assets-71.96% Debt Debt-to-Equity RatioN/A Current Ratio5.97 Quick Ratio5.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.57 per share Price / Book11.19Miscellaneous Outstanding Shares87,550,000Free FloatN/AMarket Cap$6.44 billion OptionableOptionable Beta1.36 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:ABVX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.